Mesenchymal Stem Cells Therapy in Cisplatin-Induced Nephrotoxicity

Stem cell therapy has the future to change the face of human diseases and alleviate suffering. Mesenchymal stem cells (MSCs) have generated a great deal of excitement and promise as a potential source for stem cell-based therapeutic strategies. These data provide the clue of using MSCs in the current work to modulate cisplatin-induced nephrotoxicity, the severest adverse effect of the well-known anticancer drug; cisplatin. Forty adult albino rats were used in this study; MSCs of bone marrow origin were injected into the rat tail vein one day after a single dose of intra-peritoneal injection of cisplatin. Four weeks later, the kidney was examined morphologically, histopathologically and ultra-structurally. Renal functions (urea, creatinine) as well as serum electrolytes levels (Na, K) were estimated. Cisplatin produced marked histopathological changes in rat kidney and impaired renal functions however; MSCs ameliorated cisplatin-induced nephrotoxicity both functionally and structurally to a great extent. MSCs have a potential therapeutic effect against cisplatin-induced nephrotoxicity.

Autorentext

Hanan Dawood Yassa, MBBCh, MD, Lecturer of Anatomy and Embryology, Deputy Director of Quality Assurance and Accreditation Unit, Faculty of Medicine, Bani Suif University, Egypt. She is interested in research work and recently in stem cells therapy researches. She has several publications in per reviewed journals.